129 related articles for article (PubMed ID: 29607815)
21. Preoperative Diagnosis of Neoplastic or Malignant Hürthle Cell Lesions: A Chimera?
Díaz Del Arco C; Fernández Aceñero MJ
Acta Cytol; 2018; 62(3):193-203. PubMed ID: 29723867
[TBL] [Abstract][Full Text] [Related]
22. [Hürthle-cell thyroid neoplasms: a clinical enigma].
Cannizzaro M; Fiorenza G; Garofalo L; De Maria A; Cavallaro N; Pulvirenti A; Veroux PF
Ann Ital Chir; 1999; 70(4):503-8; discussion 508-9. PubMed ID: 10573612
[TBL] [Abstract][Full Text] [Related]
23. Report of a hürthle cell neoplasm in a peripubertal girl.
Bremer AA; Feldman BJ; Iezza G; Clark OH; Rosenthal SM
Thyroid; 2007 Feb; 17(2):175-8. PubMed ID: 17316121
[TBL] [Abstract][Full Text] [Related]
24. Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid.
Máximo V; Preto A; Crespo A; Rocha AS; Machado JC; Soares P; Sobrinho-Simões M
BMC Cancer; 2004 Mar; 4():12. PubMed ID: 15043758
[TBL] [Abstract][Full Text] [Related]
25. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
[TBL] [Abstract][Full Text] [Related]
26. Solitary nodular goiter. Review of cytomorphologic features in 441 cases.
Das DK; Khanna CM; Tripathi RP; Pant CS; Mandal AK; Chandra S; Chachra K; Sharma S; Sodhani P; Singh H; Thusoo TK
Acta Cytol; 1999; 43(4):563-74. PubMed ID: 10432876
[TBL] [Abstract][Full Text] [Related]
27. Ultrasonic diagnosis for thyroid Hürthle cell tumor.
Li P; Liu P; Zhang H
Cancer Biomark; 2017 Sep; 20(3):235-240. PubMed ID: 28946558
[TBL] [Abstract][Full Text] [Related]
28. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid.
Erickson LA; Jin L; Goellner JR; Lohse C; Pankratz VS; Zukerberg LR; Thompson GB; van Heerden JA; Grant CS; Lloyd RV
Mod Pathol; 2000 Feb; 13(2):186-92. PubMed ID: 10697277
[TBL] [Abstract][Full Text] [Related]
29. Fine-needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease.
Alaedeen DI; Khiyami A; McHenry CR
Surgery; 2005 Oct; 138(4):650-6; discussion 656-7. PubMed ID: 16269293
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.
Covach A; Patel S; Hardin H; Lloyd RV
Endocr Pathol; 2017 Sep; 28(3):207-212. PubMed ID: 28660408
[TBL] [Abstract][Full Text] [Related]
31. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm.
Sorrenti S; Trimboli P; Catania A; Ulisse S; De Antoni E; D'Armiento M
Thyroid; 2009 Apr; 19(4):355-60. PubMed ID: 19355826
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation.
Deandrea M; Ragazzoni F; Motta M; Torchio B; Mormile A; Garino F; Magliona G; Gamarra E; Ramunni MJ; Garberoglio R; Limone PP
Thyroid; 2010 Oct; 20(10):1077-83. PubMed ID: 20883171
[TBL] [Abstract][Full Text] [Related]
33. [Follicular and Hurthle cell tumors of the thyroid gland. Possibilities of preoperative differential diagnosis].
Grineva EN; Goriushkina EV; Malakhova TV; Tsoĭ UA
Vopr Onkol; 2004; 50(1):41-5. PubMed ID: 15088519
[TBL] [Abstract][Full Text] [Related]
34. Hürthle cell neoplasms diagnosed by fine needle aspiration are not associated with an increased risk of malignancy.
McKee S; Wu H; Wang X; Cramer H; Lin J; Chen S
Acta Cytol; 2014; 58(3):235-8. PubMed ID: 24819535
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors of malignancy in patients with cytologically suspicious for Hurthle cell neoplasm of thyroid nodules.
Lee KH; Shin JH; Ko ES; Hahn SY; Kim JS; Kim JH; Oh YL
Int J Surg; 2013; 11(9):898-902. PubMed ID: 23916366
[TBL] [Abstract][Full Text] [Related]
36. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.
Chiappetta G; Toti P; Cetta F; Giuliano A; Pentimalli F; Amendola I; Lazzi S; Monaco M; Mazzuchelli L; Tosi P; Santoro M; Fusco A
J Clin Endocrinol Metab; 2002 Jan; 87(1):364-9. PubMed ID: 11788677
[TBL] [Abstract][Full Text] [Related]
37. Hürthle cell neoplasms of the thyroid gland: reassessment of functional capacity.
Caplan RH; Abellera RM; Kisken WA
Thyroid; 1994; 4(3):243-8. PubMed ID: 7833658
[TBL] [Abstract][Full Text] [Related]
38. [Clinical experience in Hurthle cell tumors].
Francomano F; Napolitano L; Scipione P; Savini F; Bajocchi G; Angelucci D
G Chir; 1998; 19(11-12):449-52. PubMed ID: 9882947
[TBL] [Abstract][Full Text] [Related]
39. Evidence-based criteria for adequacy in thyroid fine-needle aspiration.
Renshaw AA
Am J Clin Pathol; 2002 Oct; 118(4):518-21. PubMed ID: 12375637
[TBL] [Abstract][Full Text] [Related]
40. Immunocytochemical expression of Ki67 and laminin in Hurthle cell adenomas and carcinomas.
Pisani T; Pantellini F; Centanni M; Vecchione A; Giovagnoli MR
Anticancer Res; 2003; 23(4):3323-6. PubMed ID: 12926070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
